The development of HIV-1 protease inhibitors (HPIs) in highly active antiretroviral therapy (HAART) has dramatically decreased AIDS mortality. However, HPIs exhibit suboptimal therapeutics in vivo due to their intrinsic low oral absorption and rapid efflux via ATP-binding cassette transporters. These attributes facilitate uninhibited viral propagation and rapid selection of drug resistant HIV-1...